RxDoctor Payments Data

Bradley Weisner, MD

Urology · Matthews, NCNPI 1619910627

Payments from drug & device makers

$7,632in general payments, 2019–2025

Across 323 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Endo Pharmaceuticals Inc.$669
  • Sumitomo Pharma America, Inc.$515
  • Coloplast$485
  • AbbVie$471
  • Dendreon Pharmaceuticals LLC$431
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,49798%
  • Education$1352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,632 in reported general payments places this provider in the 70th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$126,498
Medicare patients
608
Services billed
2,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron109$86,337
MyrbetriqMirabegron105$67,790
OrgovyxRelugolix19$47,980
Tamsulosin Hcl729$11,163
Alfuzosin Hcl ErAlfuzosin Hcl374$7,999
Finasteride538$6,358
Silodosin46$5,812
Testosterone27$3,270
Trospium Chloride ErTrospium Chloride18$3,077
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst53$2,231
Trospium Chloride52$2,214
Dutasteride51$2,017
Solifenacin Succinate39$1,207
Oxybutynin Chloride ErOxybutynin Chloride59$1,180
Cephalexin60$993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$515$134,317128 claims
Astellas Pharma US IncMyrbetriq$1,089$67,790105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 434 urology providers in North Carolina.

Other urology in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →